Aclerastide
Angiotensin II Analog / AT2 Receptor AgonistRx: ResearchCompound: Investigational
Also known as: C21, Compound 21, LP2-3
Summary
Aclerastide (also known as C21) is a non-peptide/peptide-based selective AT2 receptor agonist developed primarily for wound healing and neurological repair indications. It has been investigated for diabetic foot ulcers and other tissue repair conditions in clinical trials.
Mechanism of Action
Selective agonist of the angiotensin II type 2 receptor (AT2R), promoting tissue repair, nerve regeneration, and anti-inflammatory effects without significant AT1 receptor activation.
Routes of Administration
SubcutaneousTopical
Goals & Uses
- Nerve regenerationNeurological RepairLow
- Fibrosis reductionTissue RemodelingLow
- Anti-inflammatory effectsInflammationLow
- Wound healing (diabetic foot ulcers)Tissue RepairModerate
Contraindications
- PregnancyPopulationHighPotential fetal risk or insufficient safety data
- Known hypersensitivity to aclerastide or excipientsAllergyHigh
Adverse Effects
- Local skin irritationDermatologicalUncommon
- HypotensionCardiovascularRareLow blood pressure
Drug Interactions
- ACE inhibitors / ARBsLow
Population Constraints
- Severe renal impairmentOrgan ImpairmentRelative
- Pediatric patientsAgeRelative
Regulatory Status
- European UnionInvestigationalClinical trials conducted in EU countries; no EMA approval.
- United StatesInvestigationalNo FDA approval; investigated under IND framework.
Not approved in any major jurisdiction. Investigated in Phase II clinical trials for diabetic foot ulcers. Developed by Vicore Pharma and previously by other entities.
Evidence & Sources
No sources recorded yet.